A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial-Reference-Cited by-同舟云学术

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

Published:1999-10 Issue:1 Volume:107 Page:69-79
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Wheatley Keith,Burnett Alan K.,Goldstone Anthony H.,Gray Richard G.,Hann Ian M.,Harrison Christine J.,Rees John K. H.,Stevens Richard F.,Walker Helen

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.1999.01684.x/fullpdf

Reference21 articles.

1. Proposals for the classification of the acute leukaemias (FAB cooperative group);Bennett;British Journal of Haematology,1976

2. Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival: results of the MRC AML 10 trial;Burnett;British Journal of Haematology,1996

3. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial;Burnett;Lancet,1998

4. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia;Cheson;Journal of Clinical Oncology,1990

5. Acute promyelocytic leukemia: biology and treatment;Fenaux;Seminars in Oncology,1997

Cited by 375 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study;Cancer;2024-04-06

2. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations;Journal of Clinical Oncology;2024-04-01

3. Indication of allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia: from a pediatrician’s view;Japanese Journal of Transplantation and Cellular Therapy;2024

4. De Novo AML;Pediatric Oncology;2024

5. Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity;Journal of Clinical Medicine;2023-08-25